References
- Bhandari NR , Hess LM , Parikh RC . Biomarker testing in patients diagnosed with advanced/metastatic medullary thyroid cancer in the USA. Pers. Med. 20(2), 131–142 (2023).
- Rutten-van Mölken M , Versteegh M , Nagy B , Wordsworth S . HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead. Pers. Med. 20(4), 299–303 (2023).
- Koleva-Kolarova R , Vellekoop H , Huygens S et al. Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in three health systems. Pers. Med. 20(4), 357–374 (2023).
- Koleva-Kolarova R , Vellekoop H , Huygens S et al. Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK. Pers. Med. 20(4), 339–355 (2023).
- Koleva-Kolarova R , Szilberhorn L , Zelei T et al. Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation. Pers. Med. 20(4), 305–319 (2023).
- Kovács G , Nagy D , Szilberhorn L et al. Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young. Pers. Med. 20(4), 375–385 (2023).
- Shimada R , Alden EN , Hoff K et al. SARS-CoV-2 variant identification using a genome tiling array and genotyping probes. Pers. Med. 20(1), 13–25 (2023).
- Abdi E , Latifi-Navid S . Long noncoding RNA polymorphisms and hepatocellular carcinoma and pancreatic cancer risk. Pers. Med. 20(2), 193–200 (2023).
- Aguiar PN , Matsas S , Dienstmann R , Ferreira CG . Challenges and opportunities in building a health economic framework for personalized medicine in oncology. Pers. Med. 20(5), 453–460 (2023).